Inactivation of GSK-3β by Metallothionein Prevents Diabetes-Related Changes in Cardiac Energy Metabolism, Inflammation, Nitrosative Damage, and Remodeling
Article Information
vol. 58 no. 6 1391-1402
PubMed
Published By
Print ISSN
Online ISSN
History
- December 7, 2008
- March 10, 2009
- Published in print May 21, 2009.
- Published online ahead of print March 26, 2009.
Article Versions
- Previous version (March 26, 2009 - 06:54).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2009 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Author Information
- Yuehui Wang1,2,
- Wenke Feng1,2,
- Wanli Xue2,
- Yi Tan1,2,3,
- David W. Hein4,
- Xiao-Kun Li1,5 and
- Lu Cai1,2,3,4
- 1Chinese-American Research Institute for Diabetic Complications, Wenzhou Medical College, Zhejiang, China;
- 2Department of Medicine, University of Louisville, Louisville, Kentucky;
- 3Department of Pediatrics, University of Louisville, Louisville, Kentucky;
- 4Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky;
- 5Engineering Research Center of Bioreactor and Pharmaceutical Development, Jilin Agricultural University, Jilin, China.
- Corresponding authors: Lu Cai, l0cai001{at}louisville.edu, and Xiao-Kun Li, xiaokunli{at}163.net.
Statistics from Altmetric.com
Article usage
In this Issue
June 2009, 58(6)
Inactivation of GSK-3β by Metallothionein Prevents Diabetes-Related Changes in Cardiac Energy Metabolism, Inflammation, Nitrosative Damage, and Remodeling
